XBiotech Announces Successful Completion of Phase I Portion of Pancreatic Cancer Study

XBiotech, Inc. announced that it successfully completed the Phase I portion of its 1-BETTER study, a Phase I/II randomized, double-blind, placebo-controlled clinical study to evaluate its anti-cancer drug Natrunix in combination with chemotherapy for treating pancreatic cancer.